A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of NHL907 in Healthy Adults Aged 18 to 60

What this Trial Is About

Researchers are evaluating the safety, tolerability, and pharmacokinetics of NHL907 when given as multiple oral doses to healthy adults. This phase 1, randomized, double-blind, placebo-controlled study aims to understand how the body processes NHL907 and to monitor any treatment-related side effects in healthy participants aged 18 to 60 years. Participants will be assigned to receive one of several doses of NHL907 or a matching placebo in a sequential manner. The study includes multiple dosing levels, with participants receiving oral doses of NHL907 or placebo. The study follows a multiple ascending dose design to assess the effects at different dose levels. During the trial, participants will undergo health evaluations including medical history, physical exams, vital signs, ECGs, and laboratory tests. Researchers will monitor treatment-emergent adverse events from baseline until 7 days after the last dose Day 14. Pharmacokinetic measures such as drug concentration over time and clearance will be assessed on Day 1 and Day 7. Participants are expected to comply with study procedures and restrictions throughout the study duration, which lasts until 7 days after the final dose.

A Study of NHL907 in Healthy Adult Participants